Gujarat Kidney and Super Speciality shareholders and shareholding pattern
NSE: GKSLBSE: 544666Healthcare ServicesSmall Cap
Gujarat Kidney and Super Speciality Limited · Face value ₹2 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Dec 2025 · Issue price ₹114
Last close ₹171.50down ₹2.85 (1.63%)BSE ₹171.45
Share price at the NSE close on 28 Oct 2026. Previous close ₹174.35.
28 Oct: open ₹175.51, high ₹175.51, low ₹170.61
Range of traded prices from listing on 30 Dec 2025 to 28 Oct 2026
₹98.36Low, 23 Jan 2026₹209.80High, 1 Oct 2026
- Next results date: the board meets on 4 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹1,352 Cr1,531st largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- Earlier quarters restated in the year
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 5.35
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonesince listing in Dec 2025
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 8.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.06
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 2,43,12349.5% delivered
Gujarat Kidney and Super Speciality's shareholding pattern for Sep 2026, filed on 7 Oct 2026, with every filing from Dec 2025: who owns its shares by group, its promoters by name and its public holders of 1% or more.
Who owns Gujarat Kidney and Super Speciality, filing by filing
Per cent of the company's shares.
Sep 2026 filing
- Promoters71.45%
- Foreign institutions6.53%
- Indian institutions0.26%
- Individuals and others21.77%
Shareholding pattern, per cent
- Promoters
- Foreign institutions
- Indian institutions
- Individuals and others
| Per cent | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| 71.45% | 71.45% | 71.45% | 71.45% | |
| Indian promoters | 71.45% | 71.45% | 71.45% | 71.45% |
| Public. Every shareholder outside the promoter group, the employee trusts and the shares held against depositary receipts, as the filing totals them. Public in the glossary | 28.55% | 28.55% | 28.55% | 28.55% |
| Shares in issue | 7,88,43,250 | 7,88,43,250 | 7,88,43,250 | 7,88,43,250 |
| Shares locked inShares locked in. Shares the filing reports as barred from sale until a set day, such as promoters' shares after a public issue or shares allotted to an investor directly. Shares locked in in the glossary | 6,56,16,370 | 5,68,43,250 | 5,68,43,250 | 5,63,33,725 |
| Promoters' shares locked in | 5,63,33,900 | 5,63,33,900 | 5,63,33,900 | 5,63,33,725 |
A dash is a line the filing did not state. “Under 0.01%” is a holding of shares too small to show at two decimals.
Gujarat Kidney and Super Speciality promoters
Promoters are the founders, families and companies that control the company, as its filings name them. Every member of the promoter group holding shares in the filing for Sep 2026; the largest is Pragnesh Yashwantsinh Bharpoda, 38.16%. The filing names 8 more members with no shares.
| Holder | |||
|---|---|---|---|
| Pragnesh Yashwantsinh BharpodaIndividuals and Hindu undivided families | 38.16% | 3,00,84,250 | 100.00% |
| Yashwantsingh Motisingh BharpodaIndividuals and Hindu undivided families | 11.10% | 87,50,000 | 100.00% |
| Anitaben NayakIndividuals and Hindu undivided families | 11.10% | 87,50,000 | 100.00% |
| Bhartiben Pragnesh BharpodaIndividuals and Hindu undivided families | 11.10% | 87,49,475 | 100.00% |
| Nikita Yashvantsinh BharpodaIndividuals and Hindu undivided families | 0.00% | 175 | 0.00% |
No promoter shares are reported as pledged. Locked in is the share of the holder's own shares that cannot be sold yet, as after a listing or an allotment.
Largest public holders of Gujarat Kidney and Super Speciality, filing by filing
Per cent, on the same shares as the split above.
| Holder | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Goldman Sachs Investments (Mauritius) I LtdForeign portfolio investors, category I | – | – | – | 3.50% |
| Ashika Global Finance Private LimitedCompanies | – | – | – | 1.27% |
| Citadel Securities India Markets Pvt LtdCompanies | – | – | – | 1.17% |
| Khandelwal Finance Private LimitedCompanies | 1.67% | 1.67% | 1.67% | – |
| Craft Emerging Market Fund Pcc-Citadel Capital FundForeign portfolio investors, category I | 3.89% | 1.67% | 1.67% | – |
| Astorne Capital Vcc - ArvenForeign portfolio investors, category I | 1.83% | – | – | – |
| Craft Emerging Market Fund Pcc- Elite Capital FundForeign portfolio investors, category I | 1.11% | – | – | – |
| Venus Investments Vcc - Venus Stellar FundForeign portfolio investors, category I | 1.11% | – | – | – |
A filing names every holder above one per cent, in the company's own words: an insurer's holding can carry one of its funds' names. A dash is a filing that did not name the holder, which includes holding under one per cent.
Who moved in the Sep 2026 filing
Against the Jun 2026 filing. A filing names a public holder only at 1% or more, so a holder no longer named fell under 1% or sold out.
- Foreign institutions: Goldman Sachs Investments (Mauritius) I Ltd newly named at 3.50%; Craft Emerging Market Fund Pcc-Citadel Capital Fund no longer named, from 1.67%
- Individuals and others: Khandelwal Finance Private Limited no longer named, from 1.67%; Ashika Global Finance Private Limited newly named at 1.27%; Citadel Securities India Markets Pvt Ltd newly named at 1.17%